A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Novartis
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Fred Hutchinson Cancer Center
Institute of Cancer Research, United Kingdom
DualityBio Inc.
Novartis
Evopoint Biosciences Inc.